4D Pharma IBS Drug Shows Efficacy in Trial
09 December 2021 - 9:03PM
Dow Jones News
By Kyle Morris
4D pharma PLC said Thursday that a Phase 2 trial of the Blautix
drug for irritable bowel syndrome demonstrated structural changes
in the gut microbiota of patients.
Blautix could provide a significant solution for millions of
patients with IBS, the study's chief investigator said.
4D pharma continues to await feedback from the U.S. Food and
Drug Administration regarding the results of its Phase 2 study of
Blautix, it said.
Shares in the London-listed pharmaceutical company at 0926 GMT
were up 2.9 pence, or 4.8%, at 64 pence.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
December 09, 2021 04:48 ET (09:48 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2024 to May 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about 4d Pharma Plc (London Stock Exchange): 0 recent articles
More 4d Pharma Plc News Articles